Early access
Sign in
Taking peoplePhase 4

Managing blood clot prevention after arm vein clots linked to catheters in cancer

Tests a care strategy after initial treatment in cancer patients with catheter-related arm clots.

Key facts

Who runs it
Ottawa Hospital Research Institute
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Status
Recruiting
Phase
Phase 4
People taking part
330 people, planned
Started
19 Dec 2024
Expected to end
Oct 2029
Type of study
Interventional
Treatments tested
  • Anticoagulation Therapy
Record updated
21 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active cancer who had a blood clot in an arm vein linked to a catheter. They must have had blood-thinner treatment for at least 3 months.

Age
18 years and older
Sex
All sexes
Disease stage
Active cancer: diagnosed or treated within 6 months, spread, returned or growing, on cancer treatment, or blood cancer not in complete remission. Localized non-melanoma skin cancer does not count. A confirmed catheter-related deep vein clot in the arm.
Earlier treatment
Must have had standard full-dose blood-thinner treatment for at least 3 months (LMWH lowered to 75% after the first month is allowed). Blood thinner must not have been stopped or lowered to a preventive dose for > 5 days before joining.

Main reasons for not taking part

  • Active bleeding or other reasons blood thinners cannot be used
  • Other conditions needing ongoing full-dose blood thinners, such as atrial fibrillation or a mechanical heart valve
  • Cancer in remission and the central catheter already removed
  • Platelet count < 50 x 109/L or creatinine clearance < 30 ml/min
  • Life expectancy of less than 3 months

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adult patients (≥ 18 years old) with active cancer, defined as cancer (other than localized non-melanoma skin cancer) diagnosed or treated within 6 months, or the presence of metastatic, recurrent, or progressive malignancy, ongoing anticancer therapy, or hematological malignancy not in complete remission
  • Objectively confirmed catheter-related upper extremity DVT and treated with any standard therapeutic anticoagulation (including LMWH dose reduction to 75% after the first month) for at least 3 months
  • Able and willing to provide informed consent

Who cannot take part

  • Anticoagulation has been permanently stopped or reduced to prophylactic dose for > 5 days prior to enrollment for any reasons
  • Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 and P-glycoprotein in patients who are prescribed a direct oral anticoagulant
  • Cancer is in remission and CVC is removed prior to enrollment
  • Requirement of dual antiplatelet therapies
  • Active bleeding or other reasons for which anticoagulation is contraindicated
  • Other indications requiring ongoing therapeutic dose of anticoagulation as deemed necessary by treating physicians (such as atrial fibrillation, mechanical heart valve, etc.)
  • Platelet count < 50 x 109/L or creatinine clearance < 30 ml/min
  • Pregnancy or breast feeding in patients who are prescribed a direct oral anticoagulant
  • Life expectancy of less than 3 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

The group in the trial

  • ApixabanTreatment being tested

    2.5 mg twice daily

    Treatment: Anticoagulation Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)
Plain-language title
Managing blood clot prevention after arm vein clots linked to catheters in cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
21 September 2026